JUPW - Jupiter Wellness launches trial comparing JW-100 and Eucrisa for treatment of eczema

Jupiter Wellness (JUPW) announces a head-to-head trial comparing JW-100 lotion with Eucrisa crisaborole ointment 2% for the treatment of patients with mild to moderate eczema (Atopic Dermatitis).Eucrisa is an FDA-approved topical non-steroidal lotion containing crisaborole approved for treatment of eczema.JW-100 is a non-steroidal topical lotion containing cannabidiol (cbd) and Aspertame to treat eczema. The clinical trial which will evaluate superiority between JW-100 and Eucrisa will be performed in collaboration with Applied Biology who has developed the protocols and will co-ordinate the trial. The Phase III multi-center trial will be a double-blinded placebo controlled trial. Jupiter Wellness previously reported in a previous trial of 55 patients that, JW-100, was shown to significantly reduce ISGA scores in 50% of adult patients suffering from eczema after two weeks of use.

For further details see:

Jupiter Wellness launches trial comparing JW-100 and Eucrisa for treatment of eczema